contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bioporto-helarsregnskab-for-2024-og-guidance-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

CEO, Sweden

Claus Thestrup

BioPorto is a Danish in-vitro diagnostics company with headquarters in Copenhagen, Denmark. The company was founded in 2000. BioPorto has one marketed product, the NGAL test, for early diagnosis of acute kidney injury (AKI), which is commercially available in Europe, Canada, Asia, and Israel.

It has received breakthrough designation from the FDA for AKI in the pediatric indication, for which it is currently conducting data analysis following the completion of enrollment of patients for its Phase 3 study which will lead to an expected application to FDA. Future plans include further FDA submission for adult indication as well as other markets. 

BioPorto

Bioporto: Helårsregnskab for 2024 og guidance 2025

Guidance 2024:
Oms&#xe6;tning FY 24 DKK 40 mio. og rapporteret 36,2 mio. &#xa0;afvigelse vs guidance -9,5%
Adj ebitda tab Dkk 68-73 mio. (midpoint 70,5 mio.)og rapporteret 70,6 mio. inline med tidligere udmeldinger fra 6 januar 2025.
&#xa0;
Guidance 2025:
Oms&#xe6;tning FY 25 DKK 45-60 mio +24-66% vs. 2024 rapporteret
Adj ebitda loss Dkk 75-85 mio. (midpoint 80 mio.) +6-20% vs. 2024 rapporteret. 
Oms&#xe6;tningen for 2024 er op med 17% YoY til DKK 36,2 mio. vs. DKK 31 mio. i 2023, men ned med knapt 10% vs. guidance for 2024. Det skyldes prim&#xe6;rt lavere NGAL &#x2013; RUO salg i Q4 som tidligere rapporteret den 6 januar 2025. Hvad ang&#xe5;r adj. ebitda s&#xe5; kommer selskabet ind som tidligere udmeldt, men ned i forhold til oprindelig guidance, grundet lavere omkostninger til opstart af ProNephro AKI(NGAL) til voksne samt en generel stram omkostningsstyring.
Hvad ang&#xe5;r guidance for 2025, s&#xe5; forventer selskabet en h&#xf8;j v&#xe6;kst drevet af ProNephro AKI(NGAL) til b&#xf8;rn og unge voksne - godkendt i december 2023 af FDA, drevet af partneraftalen med Roche i USA samt fortsat salg af NGAL-RUO salg. Salget vil v&#xe6;re back-end loaded. Omkostninger vil stige som f&#xf8;lge at &#xf8;get salgs- og markedsf&#xf8;ringsaktiviteter samt klinisk udvikling af ProNephro AKI(NGAL) til voksne og forberedelse af ans&#xf8;gningen til FDA.
&#xa0;Vi afholder event med Bioporto&#x2019;s CEO Peter M&#xf8;rch Eriksen samt CFO Niels H&#xf8;y Nielsen i dag kl 10:00 &#x2013; tilmeld dig her: <a href="https://www.inderes.dk/videos/bioporto-praesentation-af-helarsregnskabet-for-2024" target="_blank" rel="noopener">Dagens event</a>
Disclaimer: HC Andersen Capital modtager betaling fra Bioporto for en Digital IR/Corporate Visibility abonnementsaftale./Claus Thestrup d. 20.03 2025 kl. 08:16.